Teva and Active Biotech Expand Investigational MS Treatment Program
Prostate Cancer Therapeutics Market Competitive Landscape
Production at Teva API plant halted until next year | Fierce Pharma
Teva drops development of laquinimod - PharmaTimes
PharmaShots | Incisive News in 3 Shots
CHMP says no to Laquinimod
Teva Pharmaceutical Industries Ltd. Active Biotech AB Web Site: www.tevapharm.com Web Site: www.activebiotech.com ______
Teva abandons development of laquinimod after multiple failures
NORMAL.DOT för Office 97
ANNUAL REPORT 2020 | ACTIVE BIOTECH AB
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Active Biotech - News, Articles etc. - European Pharmaceutical Review
Fortified with sentiment and cash, Active Biotech presses on | Evaluate
Teva, Active Biotech enrol first patient in RRMS drug Phase III study - Clinical Trials Arena
Teva backs laquinimod for MS despite CHMP rejection - PMLiVE
Active Biotech regains rights of laquinimod from Teva
Teva returns laquinimod global rights to Active Biotech
Teva takes $215M hit from currency effects
Active Biotech and Ipsen to present
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
